Shanghai Henlius Biotech to convene extraordinary general meeting

Shanghai Henlius Biotech, Inc. will hold an Extraordinary General Meeting (EGM) on July 21, 2025, in Shanghai to seek shareholder approval for several key resolutions. The primary focus of the EGM is the consideration and approval of a Share Option Scheme and a Restricted Stock Unit (RSU) Scheme. Shareholders will also vote on a service provider sublimit for issuing up to 1.5% of shares under both the Share Option Scheme and the RSU Scheme, as well as authorization for the Board to handle matters related to the schemes. Additionally, approval for granting 750,000 RSUs to Dr. Jun Zhu will be sought, pending approval of the RSU Scheme. The company has set specific deadlines for proxy submissions and share transfer registrations to determine eligibility for attendance and voting at the EGM.